Alnylam Pharmaceuticals, Inc.

Day range

$224.10 – $232.48

Open

$226.24

Prev close

$224.03

Volume

1.43M

Market cap

$29.98B

Shares out

133.81M

P/E

37.10

P/S

6.24

P/B

22.14

P/FCF

37.76

ROE

59.7%

ROA

14.5%

Debt/Equity

0.75

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsMay 27, 2026

  The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified. The voting results were as follows: Stuart A. Arbuckle, Yvonne L. Greenstreet, M.D., and Elliott Sigal, M.D., Ph.D.

• Executive compensation changeMar 4, 2026

  Effective March 2, 2026 (the 'Grant Date'), the Board of Directors (the 'Board') of Alnylam Pharmaceuticals, Inc. ('Alnylam' or the 'Company') granted, following the recommendation of the People, Culture and Compensation Committee (the 'Committee'), a special equity award (the 'Special Award') under the Company's Second Amended and Restated 2018 Stock Incentive Plan (the '2018 Plan') to Yvonne Greenstreet, M.D., M.B.A., the Company's Chief Executive Officer. The Special Award is fully performance-based and provides value only upon achievement of significant stock price appreciation through December 31, 2029 (the 'Vesting Date'). The Special Award provides for a target number of 55,373 performance share units ('Target Shares'), which based on the $325.07 closing price of the Common Stock on the Grant Date, represents a face value of $18.0 million.

• Strategic initiativeJan 12, 2026

  announced its new five-year strategy, 'Alnylam 2030,' as well as its preliminary fourth quarter and full year 2025 global net product revenues and provided the Company's 2026 product and pipeline goals.

• Debt retirementDec 11, 2025

  On December 10, 2025, Alnylam Pharmaceuticals, Inc. (the "Company") entered into separate, privately negotiated repurchase agreements with certain holders of its 1.00% convertible senior notes due 2027 (the "Notes") to repurchase for cash (the "Repurchases") approximately $34.4 million aggregate principal amount of the Notes for a total repurchase cost (including accrued and unpaid interest) of approximately $51.9 million.

• Director departureDec 3, 2025

  On December 2, 2025, Michael W. Bonney and Carolyn Bertozzi, Ph.D. provided notice of each of their resignations from the Board of Directors (the "Board") of Alnylam Pharmaceuticals, Inc. (the "Company"), effective on the same date. Neither Mr. Bonney's nor Dr. Bertozzi's respective resignation was caused by any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Days to cover

6.5

Short interest

7.71M

Avg volume

1.2M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for
  negativeZacks Investment Research· Oct 26, 2026
• Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight
  positiveGlobeNewswire Inc.· Oct 22, 2026
• Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
  positiveZacks Investment Research· Oct 22, 2026
• Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
  positiveThe Motley Fool· Oct 21, 2026
• Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
  positiveZacks Investment Research· Oct 12, 2026